On July 31, 2026, HRSA released a revised version of its 340B Rebate Model Pilot Program. The pilot is scheduled for publication in the Federal Register on August 3. Under the revised model, approved manufacturers could provide the 340B discount through a rebate after purchase rather than through the traditional upfront discount.
The revised announcement follows the earlier rebate pilot, which was blocked before its planned January 1, 2026 implementation.
Key takeaway: The revised pilot does not automatically exempt CAHs, FQHCs, rural hospitals, or any other covered-entity class. Once a manufacturer’s plan is approved for an eligible drug, the rebate process may apply across covered-entity types.
How the Rebate Model Would Work
Under the traditional 340B model, covered entities generally purchase eligible medications at or below the 340B ceiling price.
Under the pilot, covered entities would instead purchase affected drugs at wholesale acquisition cost through their existing distribution channels. The covered entity would then submit claims-level data and request a rebate equal to the difference between WAC and the applicable 340B ceiling price on the date of dispense.
Approved manufacturer plans must provide covered entities with:
- At least 45 calendar days from the date of dispense to submit the required information
- Rebate payment or a documented denial within 10 calendar days after a completed submission is received
- If a submission is incomplete, the 10-day payment period would restart once the missing information is supplied.
Manufacturers would also be responsible for the cost of the required submission platform. The platform must support affected covered entities, provide real-time claim-status reconciliation, limit data collection to required information, offer technical assistance, and protect patient information in accordance with applicable privacy laws.
Which Drugs Are Included?
The pilot is limited to the applicable NDC-11s of drugs selected under the Medicare Drug Price Negotiation Program for the 2026 and 2027 initial price applicability years. The rebate model would apply during each drug’s negotiated-price period, regardless of payer or indication.
No Automatic Exemption for Rural or Safety-Net Providers
During the stakeholder process, CAHs, FQHCs, rural hospitals, and other providers raised concerns about cash flow, administrative burden, technology access, and operational readiness.
HRSA acknowledged that these concerns may affect provider types differently but declined to exclude any covered-entity category from the pilot.
Individual accommodations may still be included in a manufacturer’s plan, such as exceptions for organizations without TPA access, certain rural providers, or entities with limited operational capacity. However, these accommodations would depend on the manufacturer’s proposal and HRSA’s approval.
Cash-Flow and Patient-Access Considerations
One of the most immediate concerns is the working-capital impact of purchasing affected drugs at WAC while awaiting rebate payment.
Organizations with significant utilization of high-cost medications could have substantially more money tied up between purchase and reimbursement. The full cash-flow cycle may also extend beyond the stated 10-day payment period when claim processing, incomplete submissions, denials, and reconciliation are considered.
Covered entities should also review how the rebate model could interact with indigent-care workflows. The notice does not explain how these arrangements should be handled. Covered entities may want to identify recurring patients using affected medications and evaluate current purchasing, replenishment, and documentation processes. Patient-facing changes should likely wait until approved manufacturer plans provide clearer operational direction. Cash-flow and administrative concerns have remained central to the 340B rebate debate.
Key Dates
- August 24, 2026: Manufacturer rebate plan submissions for HRSA review due.
- September 24, 2026: HRSA anticipates notifying manufacturers whether their proposed rebate plans have been approved.
- 90 Days Before Implementation: Covered entity notice required. Notices should include registration requirements, platform instructions, submission procedures, and other operational details.
- January 1, 2027: Manufacturer plans approved through the pilot are expected to become operational at the start of 2027.
- By April 30, 2028: HRSA plans to publish an evaluation examining the pilot’s implementation, effectiveness, and impact.
What Covered Entities Should Do Now
Although the exact requirements will depend on the manufacturer plans HRSA approves, covered entities should begin evaluating their potential exposure.
Organizations should identify affected drugs and assess:
- Current utilization
- Potential WAC exposure
- Working-capital requirements
- Indigent-care workflows
- System and vendor readiness
Covered entities should also confirm whether their TPA, wholesaler, split-billing system, and contract pharmacy partners can identify affected claims, submit required data, track denials, reconcile rebate payments, and maintain sufficient audit documentation. The revised pilot also comes amid a broader increase in manufacturer claims-data requirements.
No New Public Comment Period
The July 31 announcement was issued as a Federal Register notice rather than a proposed rule and does not establish a new public-comment period. HRSA reports that it reviewed 2,449 public comments and 26 nonpublic submissions received through the Request for Information process that closed in April 2026.
The decision to implement the pilot through an operative notice may still face legal challenges.
The Bottom Line
The revised pilot is narrower than a universal rebate model because it applies only to selected Medicare-negotiated drugs and requires individual manufacturer approval. Even so, it represents a significant financial and operational change. CAHs, FQHCs, rural hospitals, and other safety-net providers should not assume they will be excluded. Covered entities should begin evaluating WAC exposure, working-capital needs, vendor readiness, and patient-access workflows ahead of the expected January 1, 2027 implementation.
ACI will continue monitoring HRSA approvals, manufacturer implementation notices, platform requirements, and potential legal developments.
Have questions about how the revised rebate model could affect your 340B program? Contact ACI to discuss your organization’s potential financial and operational impact.